AsclepiX Therapeutics, a Baltimore, MD-based clinical-stage biotech company leveraging computational biology to develop peptides for improved treatments of retinal diseases, raised $10M in Series A-3 funding.
The round was led by Perceptive Advisors with participation from the existing investors Hibiscus Capital Management Fund II and Rapha Capital Management and its managed fund, Rapha Capital PE Life Sciences Fund VI, in addition to a new outside investor.
The company intends to use the funds to expand operations and its R&D sector.
Founded by Johns Hopkins University School of Medicine researchers, initially licensing their portfolio of vascular homeostatic peptides and technologies, AsclepiX Therapeutics is a clinical stage biopharmaceutical company using computational biology to identify potent peptide regulators of vascular homeostasis with the lead candidate, AXT107, in retinal diseases.
AXT107 inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases. Both pathways are mediated by the interaction of AXT107 with integrin αvβ3 and integrin α5β1. AXT107 is presented as a microparticulate suspension suitable for intraocular injection.
FinSMEs
26/07/2023